FDA approves Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn) as a component of chemotherapy regimen to treat acute lymphoblastic leukaemia and lymphoblastic lymphoma

Approval is for use in patients allergic to E. coli-derived asparaginase (ECASP) products used most commonly for treatment. An estimated 20% of patients are allergic to standard ECASP. Study (n=102) found recommended dose would provide target level of ASP activity in 94% patients

Source:

Biospace Inc.